Enodar Biologc Corporation controls the technology rights to a fundamental advancement in the way gene and protein expression data are analyzed and interpreted. The technology is employed in a validated suite of software products; the first, GenePlus(tm) is read for market. Unlike currently available products, Enodars products permit focused hypothesis testing, thus being useful throughout the full cycle of drug development, from discovery, to safety testing and finally to human clinical trials. This greatly expands the marketability and utility of the product and thus the return on investment. The ultimate vision is that Enodars suite of products will beapplicable to a broad range of investigations from drug discovery through the development and clinical management of individual conditions
